Opening book details…
About this Medicine article
972O Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial by G. Zalcman; A-C. Madroszyk Flandin; O. Molinier; C. Dayen; T. Egenod; D. Debieuvre; S. Beaucaire-Danel; A. Dixmier; E. Pichon; S. Galland Girodet; E. Giroux-Leprieur; N. Cloarec; J. Cadranel; J. Otto; P. Romand; A. Langlais; F. Morin; M. Antoine; V. Westeel; A.C. Toffart is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- G. Zalcman; A-C. Madroszyk Flandin; O. Molinier; C. Dayen; T. Egenod; D. Debieuvre; S. Beaucaire-Danel; A. Dixmier; E. Pichon; S. Galland Girodet; E. Giroux-Leprieur; N. Cloarec; J. Cadranel; J. Otto; P. Romand; A. Langlais; F. Morin; M. Antoine; V. Westeel; A.C. Toffart
- Publisher
- Elsevier BV
- Published
- 2022
- Language
- EN
- Field
- Medicine (Health Sciences)